PFE
Pfizer Inc
Q4 2024 Report
Pfizer Inc (PFE) Q4 2024 Financial Results: Strong Revenue Growth Amid Strategic Portfolio Transformations...
Read full report
Executive Summary
In Q2 2024, Pfizer Inc experienced a resilient financial performance driven by robust execution across its core product portfolio. The company reported total revenues of $13.3 billion, reflecting a year-over-year increase of 3%, underpinned by significant growth in non-COVID product sales. Key strategic priorities, including achieving world-class oncology leadership and expanding its innovative pipeline in obesity treatment, continue to fuel growth. Management’s focus on cost realignment and operational efficiencies is anticipated to enhance future profitability, presenting a strong investment thesis as Pfizer navigates the post-pandemic landscape.
Key Performance Indicators
Revenue
13.28B
QoQ: -10.73% | YoY:0.39%
Gross Profit
8.24B
62.10% margin
QoQ: -21.48% | YoY:108.00%
Operating Income
1.88B
QoQ: -58.78% | YoY:194.80%
Net Income
24.00M
QoQ: -99.23% | YoY:101.01%
EPS
0.00
QoQ: -99.24% | YoY:101.00%
Revenue Trend
Margin Analysis
Key Insights
- Total Revenue: $13.3 billion
- Year-over-Year Growth: 3%
- Non-COVID Products Operational Growth: 14% in Q2 2024.
- Gross Profit: $8.24 billion with a gross profit margin of 62.1%, an improvement from the previous year.
- Operating Income: $1.88 billion, yielding an operating margin of 14.1%. **Net Income**: $24 million (up 101.0% YoY)